Vidofludimus
Vidofludimus is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR) . Vidofludimus, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD) . Vidofludimus also can be used for the research of fatty liver by targeting FXR[1][2][3].
Product Specifications
CAS Number
[717824-30-1]
Product Name Alternative
4sc-101; SC12267
UNSPSC
12352005
Hazard Statement
H302
Target
Dihydroorotate Dehydrogenase; FXR; Interleukin Related
Type
Reference compound
Related Pathways
Immunology/Inflammation; Metabolic Enzyme/Protease
Applications
COVID-19-anti-virus
Field of Research
Infection; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/Vidofludimus.html
Purity
99.14
Solubility
DMSO : ≥ 46 mg/mL
Smiles
O=C(C1=C(C(NC2=CC=C(C3=CC=CC(OC)=C3)C=C2F)=O)CCC1)O
Molecular Formula
C20H18FNO4
Molecular Weight
355.36
Precautions
H302
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
IL-17
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items